Showing posts with label BusinessWeek. Show all posts
Showing posts with label BusinessWeek. Show all posts

Sunday, April 1, 2012

Carnival Triumph Released to Sail After Deal Struck, Lawyer Says - BusinessWeek

AppId is over the quota
AppId is over the quota

A Carnival Corp. (CCL) (CCL) cruise liner was released to sail from a Texas port by a U.S. judge who ordered it seized March 30 in a lawsuit over a death in the Costa Concordia shipwreck off Italy.

U.S. Magistrate Judge John Froeschner released the MS Carnival Triumph yesterday from a seizure order holding the cruise liner in its home port of Galveston, said John Eaves Jr., a lawyer for the victim’s family.

The Triumph, which is owned by the same company that owns the Costa Concordia, was sought as security in a lawsuit (CCL) that was also filed March 30 in Galveston federal court by the family of Siglinde Stumpf, a German tourist who died in the shipwreck.

“The matter involving the Carnival Triumph has been resolved,” said Jennifer De La Cruz, a spokeswoman for Miami- based Carnival, the world’s largest cruise-ship operator.

The Triumph was allowed to board passengers and cargo while the seizure order was in effect. The 2,758-passenger ship provides year-round service from the Houston area to ports in the Caribbean and Mexico. It departed about 4:30 p.m. local time for a five-day trip to Yucatan and Cozumel.

Eaves said in a telephone interview earlier yesterday that the Triumph could be freed from the seizure order if the cruise line agreed to post a $10 million security bond in the German tourist’s lawsuit. Details of the resolution, which was reached about 30 minutes before the ship’s scheduled departure time, are confidential, Eaves said in an e-mailed statement.

Eaves, based in Jackson, Mississippi, said he’s part of an international consumer movement lobbying for increased oversight and safety standards in the global cruise industry. He said 16 cruise ships have sunk worldwide in the past 20 years. At least 25 people died after the Costa Concordia ran aground off Italy in January.

Eaves said he filed Stumpf’s lawsuit in Galveston to target the Triumph, which he said has “the same inadequate safety standards as the Costa Concordia, exactly the same.’’

“We’ve not been able to get Carnival’s attention, so this is our shot over the bow to let them know we’re serious about changing the law and maritime standards,” Eaves said. “We want a uniform set of safety standards, and we won’t stop until we get it.”

Carnival said on March 9 it had a net loss of $139 million in the first quarter, compared with net income of $152 million in the year-earlier period.

Fallout from the shipwreck of the Costa Concordia, which ran aground off the Italian island of Giglio, will extend through 2012, the company said in a statement accompanying its earnings release.

Carnival’s troubles compounded when another Costa Cruises ship, the Allegra, was towed to shore in the Seychelles islands in the Indian Ocean after catching fire on Feb. 27, and 22 guests on the Carnival Splendor were robbed on land in Mexico.

The case is Kai Stumpf v. Carnival Plc, 3:12-cv-0099, U.S. District Court, Southern District of Texas (Galveston).

To contact the reporter on this story: Laurel Brubaker Calkins in Houston at laurel@calkins.us.com.

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


View the original article here

Wednesday, March 28, 2012

J&J Duped Arkansas Doctors Over Risperdal, Lawyer Tells Jury - BusinessWeek

AppId is over the quota
AppId is over the quota

Johnson & Johnson (JNJ) (JNJ) officials repeatedly misled Arkansas doctors about the safety of the antipsychotic drug Risperdal, and the drugmaker should be held responsible for those deceptions, a lawyer said.

J&J’s Janssen unit made misleading claims about Risperdal’s health risks and effectiveness in a letter to more than 6,200 Arkansas doctors, violating the state’s deceptive-trade practices law, one of the state’s lawyers told a jury in Little Rock today. Arkansas is seeking more than $1.25 billion in penalties over the campaign.

“By the time this case is over, we will prove to you that Janssen lied about Risperdal’s dangers just to make money,” Fletcher Trammell, an attorney for Arkansas, told jurors in opening statements in the state-court trial over J&J’s Risperdal marketing tactics.

It’s the fifth jury trial over states’ claims that J&J, the second-biggest (JNJ) maker of health products, hid Risperdal’s diabetes risks and tricked Medicaid regulators into paying millions of dollars more than they should have for the medicine. J&J ended the most recent trial in Texas with a $158 million settlement in January. The Texas settlement won court approval today.

J&J has said it provided proper warnings about diabetes risks on Risperdal’s label and that U.S. regulators approved those disclosures. Efforts to tie labeling claims to Medicaid fraud should fail because “compliance with federal drug labeling statutes and regulations is not a condition of payment or participating in” a state Medicaid program, J&J said in a July 2010 court filing.

Janssen didn’t engage in deceptive trade practices and didn’t harm anyone, James Simpson, a company lawyer, told the jury today.

“The state will not present any evidence that a single person was injured while taking Risperdal,” Simpson said in his opening statement. “There will not be any evidence that the state of Arkansas lost a penny in paying for Risperdal for thousands of Arkansas citizens who needed the drug.”

Risperdal’s global sales peaked at $4.5 billion in 2007 and declined after the company lost patent protection. The drug generated $3.4 billion in sales in 2008, or 5.4 percent of New Brunswick, New Jersey-based J&J’s revenue (JNJ), according to company filings. Sales of the drug fell to $527 million in 2010, according to earnings reports.

Along with contending that J&J and Janssen defrauded the Medicaid program by failing to properly outline the antipsychotic medicine’s risks on the warning label, Arkansas officials allege J&J officials deceptively marketed the drug as safer and better than competing medicines.

The state also argues that the companies marketed the drug for “unapproved uses, including various symptoms in children and the elderly” after being warned by federal authorities to halt such sales, according to the state’s suit.

The U.S. has been investigating Risperdal sales practices since 2004, including allegations that the company marketed the drug for unapproved uses, J&J executives said in a U.S. Securities and Exchange Commission filing (JNJ) last year.

The U.S. Justice Department is demanding that J&J pay about $1.8 billion to resolve the civil claims by federal regulators and some state attorneys general, people familiar with the settlement talks said this month.

Arkansas is asking the jury to find J&J and Janssen liable for illegally marketing Risperdal to dupe state officials into overpaying for the drug.

The state has said it will then ask Judge Tim Fox to fine J&J at least $5,000 for each prescription affected by the Risperdal marketing campaign. Arkansas says at least 250,000 prescriptions may have resulted from illegal marketing. That would amount to a fine of at least $1.25 billion.

The state said it also will seek damages for misleading statements made in a 2003 letter to Arkansas doctors touting Risperdal. Arkansas said it will also seek penalties for more than 19,000 sales calls in which J&J representatives allegedly used the letter or made other deceptive statements about the drug.

Trammell, the state’s lawyer, said that J&J and Janssen would argue at trial that Risperdal is effective as an antipsychotic.

“And it’s true, we don’t dispute it,” Trammell told jurors. “But that doesn’t give anybody a pass to lie about dangers. Just because the drug works that doesn’t mean they can break the law by lying about the drug’s risks.”

Simpson said Risperdal’s risks are minimal. By 2002, after “12.7 million patient years” of Risperdal use, only 311 adverse blood sugar events were known worldwide, a rate of 0.002 percent, he said.

“If my math is good, .002 is 10 feet in a mile. In other words,” he said, taking a few steps toward the jury box, ’’it’s that much in a mile. Ten feet. That’s how rare these incidents happen.’’ The rate of adverse events hasn’t changed since then, he said.

J&J and Janssen have been sued by 11 states seeking reimbursement for Medicaid or other public funds paid on Risperdal prescriptions. The lawsuits allege that J&J promoted the drug for dementia, mood and anxiety disorders and other unapproved uses, or downplayed risks.

In June 2010, a judge threw out Pennsylvania’s suit over the Risperdal marketing campaign in the middle of a trial. An appeal of that ruling is set to be heard next month.

Four months later, jurors in Louisiana ordered the drugmaker to pay almost $258 million to state officials for making misleading claims about the drug’s safety. J&J has appealed.

In June 2011 a South Carolina judge ordered J&J to pay $327 million in penalties for deceptively marketing the medicine. The company has appealed that ruling.

The case is State of Arkansas v. Ortho-McNeil-Janssen Pharmaceuticals Inc., CV07-15345, Pulaski County Circuit Court (Little Rock).

To contact the reporters on this story: Margaret Cronin Fisk in Southfield, Michigan, at mcfisk@bloomberg.net; Jef Feeley in Wilmington, Delaware, at jfeeley@bloomberg.net; Eric Francis in Little Rock, Arkansas, at eric.francis@yahoo.com

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


View the original article here

Saturday, March 24, 2012

Parlux Fragrances rachat doit être bloqué, l'avocat soutient - BusinessWeek

Sale of $ 170 million of Parlux Fragrances Inc. (PARL) at Perfumania Holdings Inc. (PERF) should be blocked because the administration of Paris Hilton perfume manufacturer did not seek a higher bid, said a lawyer for the shareholders of Parlux.

Council of Parlux also failed to disclose that Perfumania threatened officials begin a proxy battle unless the offer has been accepted, the Attorney Donald j. Enright said Delaware Chancery Court Judge Sam Glasscock.

Administrators "ceded to pressure" after having been threatened by Perfumania, Enright said at a hearing today in Georgetown (Delaware). A Special Committee was appointed following the threat only evaluated the proposal and did not solicit offers of other buyers and did not block the cash option which had been part of an offer earlier.

Glasscock said that it would be to "cure quickly" and that he told the lawyers that he could issue a written notice of next week or a decision of the Court.

Parlux based in Fort Lauderdale, Florida Announces December 23 that it would sell the company at Perfumania, which operates a chain of perfume shops about 360, in a deal then valued at $ 170 million, according to a statement from the company.

"The value of this transaction has fallen very, very significantly since it was announced,"Enright said Glasscock."" Enright said that the price had "declined by approximately $ 50 million" worth a total of $ 120 million, based on the price of the shares recent the Perfumania.

Under the terms of the sale, Parlux investors can choose to receive $4 in cash, plus 0.20 share of Bellport, New York - based Perfumania or 0.53333 of the purchaser, for each share they own. Perfumania reached $10.32 percent 12 to 15: 45 in Nasdaq Stock Market trading. Parlux has lost a cent to $5.64 to 15: 45 in Nasdaq Stock Market trading.

The agreement would give Perfumania controls its largest trading partner and the manufacturer of brand perfumes famous singers of pop including Rihanna, Kanye West and Jessica Simpson.

Counsel for the Commission of said Parlux Glasscock today that they had an "active Committee" assess the offer.

"It would be a futile exercise to" society "go out and he new shop;" Alvin b. Davis, "the buyer is here," said Glasscock.

He said no other bidders have emerged for the company because the 'giant of Perfumania his head' recognized market suspended above and hazards that may result from a spurned as your largest customer purchaser.

Parlux and Perfumania official had asked Glasscock for the costume of Delaware, filed by the shareholder Parlux Jose Dias, pending, while similar combinations continue in the Court of the State of Florida. Glasscock denied this request earlier this month.

"I see nothing that indicates that this question should be suspended out of respect for the action of Florida," said Glasscock. "On the contrary, the interest in this State in the behaviour of the Trustees for its corporate citizens convinces me" to allow the prosecution to proceed, the judge added.

Counsel for media has been argued before a court on March 14 filing than Parlux administration fear to requests for Glenn Nussdorf, President of the Perfumania, sell the company, or that they face a fight on the seats of the Board of Directors.

"It seems that the threat of Mr. Nussdorf had the effect desired," Enright said in Court today.

Nussdorf, which owns 11 per cent of the shares of Parlux, placed two members to the Board of the company have expressed interest in the purchase of the manufacturer of perfume in 2006, media lawyers said in the filing.

"Any time the Commission has or the Special Committee discuss although must communicate with other contenders potentially interested parties for a market company check," counsel for the investor in the documents of the Court on 14 March.

"The idea that they were indebted to Nussdorf is mischievous and unjust," said Davis. "He was appointed because he was competent, not objectivity" he added, making reference to Anthony Agostino, one of the members of the jury selected by Nussdorf.

The case is Dias v. Purches, CA 7199, Court of Chancery of Delaware (Wilmington).

To contact the reporter on this story: Michael Bathon in New York at the mbathon@bloomberg.net

To contact the editor responsible for this story: Michael Hytha to mhytha@bloomberg.net.


View the original article here

Thursday, March 22, 2012

Arcapita Bankruptcy Was Forced by Hedge Funds, Lawyer Says - BusinessWeek

IP is over the quota
IP is over the quota

Arcapita Bank BSC, a manager of Islamic-compliant investments with $7 billion under management, was forced into bankruptcy by hedge funds that sought to be repaid in full, a lawyer for Arcapita said.

Restructuring talks on the company’s $1.1 billion loan due in March “were derailed when several hedge funds who bought that debt on the secondary market at a discount threatened an involuntary bankruptcy if they didn’t receive par” on their investments, attorney Michael Rosenthal told U.S. Bankruptcy Judge Sean Lane in Manhattan today. One of the hedge funds is Euroville Sarl, he said.

The company sought Chapter 11 protection in New York two days ago to “preclude preemptive action” and preserve its assets, Rosenthal said.

Euroville, which holds $88.7 million in the company’s debt, is concerned that some of its assets could be placed out of creditors’ reach in bankruptcy, its lawyer, David Friedman, told Lane today. “We’re afraid that tomorrow the assets will be sent to places where none of us will be able to repatriate them.”

Friedman said issues of concern include $96.3 million a year in payments to unidentified consultants, and the sale of an asset, Lusail, 14 days prior to its bankruptcy to Qatar Islamic bank (QIBK), which has a relationship with Arcapita.

Arcapita, formerly known as First Islamic Investment Bank, filed for Chapter 11 March 19 along with five affiliates, listing assets of $3.06 billion and liabilities of $2.55 billion. Arcapita Investment Holdings Ltd., already in U.S. bankruptcy, has also filed a bankruptcy in the Cayman Islands in aid of the Chapter 11 proceeding.

The two filings were made to avoid “an involuntary and value-destructive straight liquidation proceeding in the Cayman Islands,” Arcapita said in court papers.

The company’s investments, which have included U.S. brand names such as Caribou Coffee and Church’s Chicken, now include Irish power utility Viridian Group Ltd. (VRD), and U.S.-based Falcon Gas Storage Co. Other assets include interests in PODS, a portable moving and storage company founded in Florida, and Tensar International Corp., a provider of soil technologies based in Atlanta, Arcapita said in court papers.

Lane today granted the company’s “first-day” requests that will allow it to keep operating in bankruptcy. He approved its request for a court order specifying that foreign creditors can’t seize its assets.

He also said the company can jointly administer its units in bankruptcy, and have extra time to file reports of its financial information. Arcapita now has until May 3 to file a full list of assets and debts.

Arcapita can also continue to use its cash management system. The company said its funds invested in short term investments will be deposited with JPMorgan Chase in New York as they mature. Over the next four weeks, $100 million is expected to be deposited, Arcapita said in court papers.

Founded in 1996, the Manama, Bahrain-based company manages Shari’ah-compliant, or Islamic-compliant, investments and operates as an investment bank, according to the filing.

“This global recession has hampered the Arcapita Group’s ability to obtain liquidity from the capital markets, and has also resulted in a reduction in asset values,” lawyers for the company wrote in its first-day filings.

Arcapita had failed to reach an agreement with creditors on a $1.1 billion syndicated shari’ah-compliant loan due this month. Royal Bank of Scotland Plc had led a coordinating committee of lenders that sought to negotiate a restructuring, a person familiar with the plan said Feb. 27.

Central Bank of Bahrain was listed as the largest creditor, with a $255.1 million claim tied to a bank loan. Commerzbank AG (CBK) has a $164.7 million claim also related to a loan and National Bank of Bahrain has a $132.3 million claim. Bahrain’s central bank said it was monitoring the case.

Rosenthal said that after the company sought court protection, it didn’t have as many first-day requests as might be expected because the process was so rushed due to the demands of the hedge funds.

“The last 10 days have been extremely stressful and frenetic,” Rosenthal said.

The case is Arcapita Bank BSC, 12-11076, U.S. Bankruptcy Court, Southern District of New York (Manhattan).

To contact the reporter on this story: Tiffany Kary in New York at tkary@bloomberg.net

To contact the editor responsible for this story: John Pickering at jpickering@bloomberg.net


View the original article here

Saturday, March 17, 2012

Gupta's Lawyer Says 'Wrong Man' on Trial in Insider Case - BusinessWeek

AppId is over the quota
AppId is over the quota

A lawyer for former Goldman Sachs Group Inc. (GS) director Rajat Gupta, accused of passing nonpublic information to Galleon Group LLC fund manager Raj Rajaratnam, said today that the U.S. had the “wrong man” on trial.

Gupta’s lawyer, Gary Naftalis, said that Rajaratnam had a different Goldman Sachs tipper, who gave him confidential information about Intel Corp. (INTC) and Apple Inc. (AAPL), the lawyer said. That Goldman source was also caught on government wiretaps passing the inside information, Naftalis said.

Gupta, 63, who denies wrongdoing, is scheduled to go on trial May 21 for leaking tips to Rajaratnam about Goldman Sachs and Procter & Gamble Co. (PG), where Gupta was also a director.

“There are wiretaps, wiretaps that they’ve had for years, that this confidential information is being given out,” Naftalis argued today.

“The fact is important because we have the issue that you have the wrong man on trial here,” Naftalis said. “They know that there is a person at Goldman Sachs who has leaked inside information on at least two securities, on Apple and Intel, to Mr. Rajaratnam. It is certainly clear to us this is hot information. We intend to press on this issue. We think there is a much more circumstantial case that that person should be sitting in the box than us.”

Prosecutors disclosed in a Feb. 3 letter to U.S. District Judge Jed Rakoff, who is presiding over the case, that Rajaratnam had a second “insider at Goldman Sachs” who leaked tips to Rajaratnam. Rakoff has referred to this individual as “Mr. X.”

Prosecutors also said the tips didn’t relate to Goldman Sachs or Procter & Gamble.

Lawyers didn’t identify the Goldman Sachs insider in court today. Michael DuVally, a spokesman for Goldman Sachs, declined to comment on Naftalis’s assertions.

The assertions came today after Assistant U.S. Attorney Reed Brodsky said that Rajaratnam’s lawyers had been sharing government memos on witnesses who testified against the fund manager at his trial last year.

Brodsky asserted that while Gupta’s defense team has claimed they haven’t gotten evidence from prosecutors and sought the identity of “Mr. X,” defense lawyers already had evidence provided by Rajaratnam, including a copy of a memorandum of a Jan. 11, 2011, interview by agents of the Federal Bureau of Investigation with former Galleon portfolio manager Adam Smith. Brodsky said today Gupta’s lawyers claimed at a January hearing that they didn’t know who the Goldman insider was.

“They started making accusations that Mr. Gupta has no idea who the Goldman insider was who was providing nonpublic information,” Brodsky said. “A Jan. 11, 2011, memo of Adam Smith’s interview contains all that information,” he said.

Rakoff later reviewed the letter from the government identifying that individual and agreed with prosecutors to keep it under seal because the alleged tips weren’t related to any of the charges against Gupta.

“They have nothing to do with any issue in this case, directly or indirectly, and therefore do not need to be disclosed,” Rakoff said in February. He didn’t rule on the matter today saying, “I don’t think any court action is required, one way or another.”

Rakoff hasn’t yet ruled on whether he’ll permit Gupta’s lawyers to present the evidence of another Goldman source to the jury.

Naftalis declined to comment after court, as did prosecutors.

Gupta, the one-time McKinsey & Co. leader and former director at Procter & Gamble, was accused in October by Manhattan U.S. Attorney Preet Bharara of passing inside information to Rajaratnam, co-founder Galleon Group LLC. The U.S. says Gupta tipped Rajaratnam about Goldman Sachs and P&G earnings.

A revised indictment filed in January expanded prosecutors’ description of the insider-trading scheme, saying it began in March 2007, not in 2008, as the U.S. alleged when Gupta was first charged in October.

Rajaratnam, who was convicted by a jury last year of all 14 counts against him, is serving an 11-year prison term.

The case is U.S. v. Gupta, 11-cr-00907, U.S. District Court, Southern District of New York (Manhattan).

To contact the reporter on this story: Patricia Hurtado in New York at pathurtado@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net


View the original article here